GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)

BOM:500660 Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	14,035	641.71	349.41	2,862	4,052
Short-Term Investments	11,183	9,794	11,009	21,791	7,320
Trading Asset Securities	-	8,132	5,183	3,656	-
Cash & Short-Term Investments	25,218	18,568	16,541	28,309	11,372
Cash Growth	35.81%	12.25%	-41.57%	148.94%	7.10%
Accounts Receivable	2,926	2,221	1,924	2,052	2,156
Other Receivables	-	1,275	1,373	715.31	254
Receivables	2,926	3,496	3,297	2,768	2,410
Inventory	4,817	5,250	4,600	5,347	5,467
Prepaid Expenses	-	206.18	149.6	139.26	146.49
Other Current Assets	1,138	463.33	355.04	517.62	2,631
Total Current Assets	34,099	27,984	24,943	37,080	22,026
Property, Plant & Equipment	2,839	3,107	3,151	3,254	3,554
Long-Term Investments	-	0.27	0.27	0.15	0.15
Other Intangible Assets	133.3	235.54	340.91	344.97	433.64
Long-Term Deferred Tax Assets	1,409	1,463	1,335	1,131	1,031
Other Long-Term Assets	2,601	2,776	2,795	2,621	4,101
Total Assets	41,081	35,566	33,266	46,333	31,146
Accounts Payable	7,083	6,254	4,278	5,793	4,661
Accrued Expenses	-	1,655	1,482	4,622	2,066
Current Portion of Long-Term Debt	-	-	-	-	0.24
Current Portion of Leases	74.6	121.96	120.84	124.53	143.53
Current Income Taxes Payable	5,245	2,986	2,962	2,962	1,637
Current Unearned Revenue	-	-	-	-	1,800
Other Current Liabilities	6,649	4,233	4,421	3,483	3,238
Total Current Liabilities	19,052	15,249	13,264	16,984	13,546
Long-Term Leases	24.9	64.69	34.55	76.24	202.5
Other Long-Term Liabilities	2,491	1,673	1,761	1,848	1,817
Total Liabilities	21,568	17,790	15,853	19,703	16,364
Common Stock	1,694	1,694	1,694	1,694	1,694
Retained Earnings	-	16,351	15,920	25,210	13,345
Comprehensive Income & Other	17,819	-268.57	-201.58	-274.96	-256.9
Shareholders' Equity	19,513	17,776	17,413	26,630	14,783
Total Liabilities & Equity	41,081	35,566	33,266	46,333	31,146
Total Debt	99.5	186.65	155.39	200.77	346.27
Net Cash (Debt)	25,118	18,382	16,386	28,108	11,026
Net Cash Growth	36.65%	12.18%	-41.70%	154.93%	8.10%
Net Cash Per Share	148.29	108.51	96.73	165.92	65.08
Filing Date Shares Outstanding	169.38	169.41	169.41	169.41	169.41
Total Common Shares Outstanding	169.38	169.41	169.41	169.41	169.41
Working Capital	15,047	12,735	11,679	20,096	8,481
Book Value Per Share	115.21	104.93	102.79	157.19	87.26
Tangible Book Value	19,380	17,541	17,072	26,285	14,349
Tangible Book Value Per Share	114.42	103.54	100.77	155.16	84.70
Land	-	36.8	36.8	22.49	22.49
Buildings	-	1,099	1,084	1,041	1,022
Machinery	-	4,489	4,244	3,937	3,915
Construction In Progress	-	139.3	203.12	305.02	132.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.